NEW YORK – Metabolon said Thursday that it has closed on a new $60 million credit facility.
The Morrisville, North Carolina-based metabolomics firm said it will use the funds to support growth initiatives and expand research and development efforts enhancing its metabolomics platform.
The funds will also support Metabolon's global expansion plans including market penetration efforts and strategic partnerships.
The financing was led by Trinity Capital and enabled early retirement of the company’s previous $35 million debt facility. It follows a $25 million equity financing Metabolon closed in January 2023.
"This infusion of additional capital and robust process leading up to it underscore the strong investor confidence in Metabolon’s vision, capabilities, and market potential within the multiomics and metabolomics industry," Metabolon CEO Rohan Hastie said in a statement. "As the life sciences embrace a sophisticated multiomics paradigm, Metabolon is emerging as an industry benchmark and an essential catalyst toward achieving true precision medicine. This investment will enable us to accelerate growth, drive innovation, and further solidify our position as a leader in the metabolomics space."
"We are excited to partner with Metabolon, a company that has demonstrated innovation and excellence in the life sciences sector," Rob Lake, senior managing director of life sciences at Trinity, said in a statement. "By leveraging their cutting-edge technology and extensive experience, the team has the potential to accelerate research, and we look forward to supporting the company’s ongoing growth and expansion in the industry."